This content is machine translated Special report: maintenance therapy of relapsed ovarian cancer. Niraparib approved with individual starting doses In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula®) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation…
